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Abstract: Tedizolid phosphate has high activity against the Gram-positive microorganisms 
mainly involved in acute bacterial skin and skin structure infections, such as strains of Staphylo-
coccus aureus (including methicillin-resistant S. aureus strains and methicillin-sensitive S. aureus 
strains), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus anginosus group, 
and Enterococcus faecalis, including those with some mechanism of resistance limiting the use 
of linezolid. The area under the curve for time 0–24 hours/minimum inhibitory concentration 
(MIC) pharmacodynamic ratio has shown the best correlation with the efficacy of tedizolid, 
versus the time above MIC ratio and the maximum drug concentration/minimum inhibitory 
concentration ratio. Administration of this antibiotic for 6 days has shown its noninferiority 
versus administration of linezolid for 10 days in patients with skin and skin structure infections 
enrolled in two Phase III studies (ESTABLISH-1 and ESTABLISH-2). Tedizolid’s more favor-
able safety profile and dosage regimen, which allow once-daily administration, versus linezolid, 
position it as a good therapeutic alternative. However, whether or not the greater economic cost 
associated with this antibiotic is offset by its shorter treatment duration and possibility of oral 
administration in routine clinical practice has yet to be clarified.
Keywords: tedizolid, tedizolid phosphate, acute bacterial skin and skin structure infections, 
oxazolidinone, linezolid resistance
Introduction to the management of acute bacterial 
skin and skin structure infections
An acute bacterial skin and skin structure infection (ABSSSI) is defined as “a bacterial 
infection of the skin with a lesion size area of at least 75 cm2 (lesion size measured by 
the area of redness, edema, or induration).”1 This definition was included in a guidance 
document prepared by the US Food and Drug Administration (FDA) with the aim of 
guiding the development of new antimicrobial agents for ABSSSI. ABSSSIs include 
cellulitis and/or erysipelas, wound infection, and major cutaneous abscesses.
In recent years, there has been a considerable increase in the number of emergency 
department visits that may be attributed to bacterial skin and skin structure infections 
(SSSIs).2 This type of infection was diagnosed in 1.2 million visits in 1993 versus 3.4 
million visits in 2005 (95% confidence interval [CI]: 2.8–4.1; P,0.001) in a study 
conducted in emergency departments in the USA.2 At the same time, SSSIs were 
diagnosed in 1.35% (95% CI: 1.07–1.64) of all emergency department visits in 1993 
versus 2.98% (95% CI: 2.40–3.56) in 2005 (P,0.001).2
The microorganisms commonly involved in ABSSIs are Streptococcus pyogenes 
and Staphylococcus aureus strains, including methicillin-resistant strains. Streptococcus 
spp., Enterococcus faecalis, and Gram-negative bacteria must also be considered to 
a limited extent.1
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The reported increase in the number of SSSIs paralleled 
the emergence of methicillin-resistant S. aureus (MRSA) 
strains in the community.2 In a study conducted in eleven 
emergency departments in the USA in August 2004, MRSA 
strains were isolated in 59% of patients with an SSSI (range: 
15%–74%).3 MRSA was the main microorganism isolated 
in ten of the eleven emergency departments included in the 
study. A total of 216 (99%) of the 218 MRSA strains ana-
lyzed had characteristics of community-acquired MRSA. 
Among them, the USA 300 strain was isolated in the major-
ity of cases (212 [98.1%]). These results were reproduced 
in a subsequent prevalence study conducted in 12 hospital 
emergency departments in the USA in August 2008.4 How-
ever, variability based on site was lower in this year (range: 
38%–84%).
At the same time, the prevalence of MRSA in SSSIs was 
46% in 96 patients with these infections enrolled in a study 
conducted in an emergency department in a Los Angeles 
hospital.5 The rate of MRSA SSSIs increased from 29% 
in 2001–2002 to 64% in 2003–2004. The prescription of 
antibiotics with activity against community-acquired MRSA 
strains has paralleled this microorganism’s epidemiology. 
From 1993 to 2001, this was limited, but in 2005, it increased 
to 38% (95% CI: 30–45; P,0.001).2
The data from studies conducted in Europe have shown 
a similar situation.6 In a study conducted at 106 sites in 
19 European countries, S. aureus strains were isolated in 
32.6% of 3,000 strains associated with SSSIs.7 More than 
50% of these corresponded to MRSA strains.
The increase in the prevalence of community-acquired 
MRSA strains has greatly impacted the selection of empiri-
cal antibiotic treatment for ABSSSIs (Table 1). Thus, for 
treating an abscess, the Infectious Diseases Society of 
America guidelines recommend, in addition to incision and 
drainage, administering an antibiotic active against MRSA 
when the initial antibiotic treatment has failed or when the 
patient has immunosuppression or systemic inflammatory 
response syndrome and hypotension.8 In the case of cellulitis 
and erysipelas, including an antibiotic with activity against 
MRSA, as well as against streptococcus, is recommended 
when the infection is associated with penetrating trauma or 
when there is evidence of MRSA infection, MRSA coloniza-
tion, parenteral drug use, or systemic inflammatory response 
syndrome.8 Finally, including an antimicrobial agent active 
against MRSA in the treatment of surgical wound infections 
is recommended in patients with risk factors for infection by 
this microorganism (nasal colonization or prior infection, 
hospitalization, or recent antibiotic administration).8
These guidelines were published before the FDA 
approved other antibiotics with activity against Gram-positive 
microorganisms, including MRSA, in ABSSSIs. These 
include tedizolid, belonging to the oxazolidinone family, and 
dalbavancin and oritavancin, both belonging to the lipogly-
copeptide group. The therapeutic role of these compounds 
was evaluated in a previous review.9 Tedizolid’s different 
pharmacological and microbiological characteristics and 
efficacy in SSSIs will be discussed throughout this review. 
Regarding lipoglycopeptides, both oritavancin and dalba-
vancin may be suitable alternatives in patients with a history 
of prior catheter-related complications and patients who are 
candidates for receiving antibiotic treatment on an outpatient 
basis or with low adherence to oral antibiotic treatment.9 In 
addition, oritavancin is the only glycopeptide that shows 
activity against vanA-mediated vancomycin-resistant 
Enterococcus spp., which positions this antimicrobial agent 
as a good treatment option in infections caused by these 
microorganisms.9 However, some issues related to these 
compounds remain to be clarified.9 Notable among them is 
the absence of safety data related to the long-term administra-
tion of multiple doses of these antimicrobial agents, which 
Table 1 empirical treatment of acute bacterial skin and skin 
structure infections
Type of acute bacterial skin or skin structure infection
Abscess
Mild incision and drainage
Moderate 1. incision and drainage
2. Cotrimoxazole or doxycycline
Severe 1. incision and drainage
2. vancomycin, daptomycin, linezolid, 
telavancin, or ceftaroline
Cellulitis/erysipelas
Mild Oral treatment: penicillin vK, 
cephalosporin, dicloxacillin, or 
clindamycin
Moderate iv treatment: penicillin, ceftriaxone, 
cefazolin, or clindamycin
Severe vancomycin + piperacillin/tazobactam
Surgical wound infection
Clean surgery of the trunk,  
head and neck, or limbs
1. incision and drainage
2. Cefazolin or penicillin active 
against MSSA
3. vancomycin, linezolid, daptomycin, 
telavancin, or ceftaroline if risk 
factors for MRSA
Surgery of the axilla, gastro-
intestinal tract, perineum,  
or female genital tracta
1. Cephalosporin + metronidazole
2.	Levofloxacin	+ metronidazole
3. Carbapenem
Note: aAntibiotics active against Gram-negatives and against anaerobes, such as a 
cephalosporin	or	fluoroquinolone	combined	with	metronidazole.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
sensitive S. aureus; iv, intravenous.
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is very important for being able to identify their positioning 
in ABSSSIs.9 However, studying this issue will not be free 
from complications in the case of some compounds such as 
oritavancin and dalbavancin, given that they are administered 
in one, or one or two doses, respectively.
Pharmacology
Tedizolid phosphate (TR-701) is an inactive synthetic com-
pound that is rapidly hydrolyzed by phosphates in the body 




Similar to linezolid, tedizolid has a class pharma-
cophore group, the 3-(3-fluorophenyl)-oxazolidinone ring 
(ring A), which places these antimicrobial agents in the 
oxazolidinone family.
Both compounds have a lateral chain at C-5 of ring A 
that grants them greater potency against microorganisms 
susceptible to this family of antibiotics (Gram-positive micro-
organisms and mycobacteria). However, there are structural 
differences between the two antimicrobial agents. The C-5 
methylcetamide chain of the linezolid oxazolidinone ring is 
replaced by a hydroxymethyl group in tedizolid. This struc-
tural modification was initially associated with a decrease in 
its potency. Subsequently, it was observed that the addition 
of the methyltetrazole ring to D not only offset this lower 
activity of tedizolid but also increased its antimicrobial 
potency versus linezolid.12
In addition, after evaluating several prodrugs with the 
aim of increasing the bioavailability of tedizolid, it was 
found that phosphorylation at C-5 (monophosphate ester) 
increased water solubility and stability in the pH range 
from 3 to 7 and facilitated rapid hydrolysis by nonspecific 
endogenous phosphatases.13
In addition, it will also represent an improvement in 
the interaction profile with monoamine oxidase (MAO) 
(Figure 1). As a result, it is administered in the form of tedi-
zolid phosphate both orally and intravenously.
Mode of action
Similar to linezolid, tedizolid exerts its bacteriostatic activity 
by inhibiting bacterial protein synthesis by binding to the 
23S rRNA of the 50S ribosomal subunit, thus preventing the 
formation of the 70S ribosomal initiation complex formed 
by binding the 50S, 70S, and N-formylmethionine-tRNA 
subunits. It interrupts the translation process by blocking 
the alignment of aminoacyl-tRNA at the peptidyl transferase 
site, thereby interrupting peptide elongation and the start of 
protein synthesis.14–17
Pharmacokinetics
The use of tedizolid phosphate, the phosphorylated prodrug, 
increased the solubility of tedizolid, the active compound in 
Figure 1 Structure–activity differences between tedizolid and linezolid.





water, which increased its bioavailability, given its lipophilic 
character.18 Following oral administration, tedizolid phosphate 
is rapidly converted to the active drug tedizolid by apical alka-
line phosphatases, nonspecific enzymes located in the mem-
branes of multiple cells in the body. Without these enzymes, 
intestinal absorption of the prodrug would be limited.19
The bioavailability of tedizolid following administration 
of a single oral dose of tedizolid phosphate 200 mg was 
91.5%.20 The pharmacokinetics of tedizolid phosphate in 
healthy subjects was similar following oral and intravenous 
administration, so it is not necessary to perform a dose 
adjustment when switching from the intravenous route to 
the oral route.20
Lower bioavailability values have been reported in other 
studies that have included populations from far eastern coun-
tries such as the People’s Republic of China (85.5% [90% CI: 
69.3–105])21 and Japan (82.6% [90% CI: 77.9–87.6]).22
Although one study observed a delay in absorption and 
lower maximum drug concentration (C
max
) values following 
administration of a single dose of tedizolid phosphate 600 mg 
together with food, the area under the curve (AUC) and t
1/2
 
parameters remained unchanged, and so tedizolid phosphate 
may be administered with or without food.23
After analyzing the parameters from seven clinical 
trials, Flanagan et al24 established that the pharmacokinetics 
of tedizolid fits a two-compartment model with sigmoidal 
absorption, absolute bioavailability, and linear elimination.
An initial study by Flanagan et al20 sought to determine 
the pharmacokinetics of single escalating doses or multiple 
escalating doses of intravenous tedizolid phosphate as well 
as determine its oral bioavailability in healthy subjects.
First, the pharmacokinetics of single escalating doses 
of tedizolid phosphate administered intravenously (placebo 
or tedizolid phosphate 100, 200, or 400 mg) was studied. 
Second, placebo or tedizolid phosphate 200 or 300 mg was 
administered intravenously on a double-blind basis once daily 
for 7 days. Third, the absolute bioavailability of a 200 mg 
dose of oral tedizolid versus a 200 mg dose of intravenous 
tedizolid was evaluated. The two administrations were sepa-
rated by a 7-day washout period.
Following intravenous administration of tedizolid phos-
phate 200 mg, plasma tedizolid phos phate concentrations 
reached a plateau at 15 minutes and subsequently its plasma 
levels decreased rapidly until arriving at plasma concentra-
tions below the detection limit 2 hours after the start of the 
infusion. At the same time, plasma tedizolid phosphate levels 
were undetectable following oral administration of 200 mg 
of the antimicrobial agent. In addition, either tedizolid 
phosphate was not detected in urine or only 0.005% of the 
administered dose was detected.
The results of the aforementioned studies led to sub-
sequent studies seeking to study the pharmacokinetics of 
tedizolid, the active compound.20
Unlike tedizolid phosphate, the plasma concentration 
of tedizolid increased in an escalating manner following 
administration of single ascending doses of tedizolid 
phosphate intravenous (100–400 mg).20 A dose-dependent 
increase of tedizolid was observed for tedizolid’s C
max
 




0–∞, suggesting linear pharmacokinetics.
The mean steady-state apparent volume of distribution 
(V
dss
) was 61.2–74.5 L, and the mean of the elimination kinetic 
parameters was 9.3–13.4 hours for t
1/2
 and 4.8–5.8 L/h for 
clearance (Cl). In these cases, the parameters were dose 
independent.
However, oral administration of single escalating doses 
of tedizolid phosphate (200, 400, 600, 800, and 1,200 mg) 
under fasting conditions (10 or more hours before and 4 
hours after administration of the drug) yielded escalating 
C
max
 values, but they were no longer proportional to the 
administered dose. By contrast, AUC values did retain this 
proportionality, mainly with the administration of lower 
doses. The t
1/2
 was higher at 10 hours for all administered 
doses.23
Tedizolid phosphate reached the steady state in 3 days,21 
and once reached, it accumulated minimally and predictably. 
Drug accumulation ratio calculated in day 3 for C
max
 was 
1.16 (17.7%; range: 0.861–1.61) after intravenous admin-
istration. Similarly, the accumulation of tedizolid was 28% 
following intravenous administration of tedizolid phosphate 
200 mg once daily for 7 days in a different study.20 Tedizolid 
exposure was slightly greater on day 7 than on day 1 (C
max
 
3.0 [0.7] mg/mL and 2.3 [0.6] μg/mL, respectively; AUC
0–24
 
29.2 (6.2) mg×h/mL and 22.3 [4.2] mg×h/mL, respectively). 
On day 1, tedizolid’s Cl was 6.4 (1.2) L/h and its V
d
 was 77.6 
(15.9) L. On day 7, tedizolid’s Cl was 5.9 (1.4) L/h and its V
d
 
was 80.1 (21.0) L. Again, these values were not proportional 
to the administered dose. The mean 24-hour urine recovery 
of tedizolid was approximately 1% on both day 1 and 7.20
After administering multiple doses of oral tedizolid 
phosphate (200, 300, or 400 mg for 21 days under fasting 
conditions), dose-proportional increases in tedizolid C
max
 
and AUC values at day 15 (200 mg) or at day 21 (300 and 
400 mg) were observed.23 This contrasted with the kinet-
ics of linezolid after administering doses of 600 mg every 
12 hours for 21 days under fasting conditions, given that 
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with linezolid a greater accumulation at steady state was 
observed (~72%).23 Linezolid steady-state C
min
 were 3.9 
and 8.02 mg/L, after multiple oral doses of 375 and 625 mg 
given every 12 h for 14 days, respectively.25 C
max
 were 13.2 
and 18.8 mg/L, respectively.
In the previous, tedizolid Cl was generally independent 
of both dose and the number of doses administered, while 
oral Cl of linezolid Cl decreased with the number of admin-
istrations.23 Clearance values at steady state were 10–30% 
lower with multiple oral administration and 11–19% lower 
with multiple intravenous administration compared with 
single dose.26 Values for t
1/2
 of linezolid 600 mg were 3.80 
(1.67) hours on day 1 and 5.75 (1.15) hours on day 21.23 
Mean tedizolid t
1/2
 was approximately 2-fold higher than 
that of linezolid.
The active drug tedizolid is a lipophilic compound 
with high penetration in plasma, interstitial fluid, muscle 
and adipose tissue, epithelial lining fluid, and pulmonary 
alveolar macrophages, and this is based on data from studies 
performed using microdialysis. Thus, plasma concentrations 
of tedizolid may be used as a direct surrogate for tissue 
concentrations.24,27,28 The ratio of penetration into the epithe-





were approximately 40-fold and 20-fold, respectively, in 20 
healthy adults.27
One study involved administering a single dose of 
tedizolid in both animals and humans.29 In vitro plasma pro-
tein binding of tedizolid was 97.7% in rats, 92.6% in mice, 
78% in dogs, and 84.6% in humans.29
The V
d
 of tedizolid was more than double the value 
observed with linezolid (V
d
: 101 L versus 40–50 L).29 
After the dose, 87.6% of radioactivity was recovered at 
96 hours, and 99.5% of radioactivity was recovered at 
288 hours. Recovery in feces was 81.5%, and recovery in 
urine was 18%. In both feces and urine, tedizolid accounted 
for only 3% of recovery, whereas, in plasma, it was the 
main form.
Similar to another study in healthy adults, it showed 
plasma protein binding ranging from 86.1% to 91.9%.27 
This plasma protein binding was considerably higher than 
that of linezolid (31%).25
Tedizolid is mainly metabolized by the liver. Tedizolid 
sulfate is the major isolated metabolite in both feces (69% 
[56.81–79.49%]) and urine (10% [7.17–14.2%]). This 
metabolite’s antimicrobial activity is very limited. Other 
minor isolated metabolites were carboxy tedizolid and 
desmethyltedizolid. Among these, only desmethyltedizolid 
seemed to retain antimicrobial activity.29
Regarding the formulation of oral tedizolid phosphate, 
Flanagan et al23 demonstrated similar pharmacokinetics after 
administration of tedizolid phosphate powder form from a 
capsule or tablet formulation. Kennedy et al30 evaluated the 
stability and recovery of the dose contained in the tedizolid 
phosphate capsule after it was crushed and dispersed in 
water. The recovery of tedizolid phosphate was greater than 
93% of the initial dose after simulating its passage through 
two different types of nasogastric tubes. The reconstituted 
solution remained stable for 4 hours at room temperature, 
with minimal degradation of the initial administered dose. 
These findings ensure the possibility of crushing the tablet 
for patients with swallowing problems.
Special populations
Pharmacokinetic studies conducted by Flanagan et al24 
in different populations (healthy adults, patients with 
ABSSSIs and patients with different degrees of organ dam-
age enrolled in Phase I and III trials) indicated that none of 
the “clinical covariates” (age, sex, race, body mass index 
[BMI], renal failure, or hepatic failure) significantly affected 
tedizolid exposure.
The pharmacokinetic behavior of tedizolid showed 
no variation after it was evaluated in adolescent subjects 
(12–17 years).31 Mean tedizolid AUC values for adolescents 
were within 15% of previously reported adult values after 
oral or intravenous administration of a single dose of 200 mg 
tedizolid phosphate (geometric mean ratio (90% CI) of AUC 
adolescents/AUC adults after 200 mg of single dose oral 
administration was 0.847 mg×h/mL [0.736–0.975]).
Mean C
max
 value was similar to adults after oral admin-
istration of a single dose of 200 mg. However, this value 
was ~43% higher in adolescents after intravenous admin-
istration than in adults (3.66 mg/mL versus 2.55 mg/mL, 
respectively).
There are no data in populations under 12 years of age. 
These results are in contrast with the pharmacokinetic data for 
linezolid in a population between 3 months and 16 years of 
age, in which availability of linezolid was age-dependent and 
Cl and V
d
 were higher compared to the adult population (mean 
values for Cl and V
d
 were 0.34±0.15 L/h/kg and 0.73±0.18 L/
kg, respectively). This led to the need to apply a special dos-
age regimen in this age-group (10 mg/kg 2–3 times/d).32
At the same time, the pharmacokinetic data for admin-
istering a single dose of tedizolid 200 mg to 40 subjects 
over 65 years of age versus 14 subjects ranging from 18 to 
45 years of age demonstrated an approximately 9% increase 
in the geometric mean ratio of the C
max
 and an approximately 





13% increase in the geometric mean ratio of the AUC.33 No 
discontinuation of treatment because of adverse events was 
required. For all these reasons, similar to linezolid,25 no 
dose adjustment seems necessary for oral administration of 
tedizolid phosphate in those over 65 years of age.
One study evaluated the pharmacokinetics of tedizolid 
in obese patients (BMI $30 kg/m2) and severely obese 
patients (BMI $35 kg/m2).34 According to the results, the 
pharmacokinetics was similar to those observed in nonobese 
patients, independently of the degree of obesity, and so a dose 
adjustment is not required in this population.
According to the results of this study, only ideal body 
weight (IBW) showed a statistically significant relationship 
to the pharmacokinetics of tedizolid.34 However, this finding 
was not considered to be clinically significant. Regarding 
linezolid, one study in 20 healthy obese volunteers (BMI: 
30–54.9 kg/m2) demonstrated similar exposure to the anti-
microbial agent after administering five doses of 600 mg 
IV every 12 hours (AUC for the 12 hour dosing interval 
was 130.3±60.1 mg×h/mL for moderately obese patients 
and 109.2±25.5 mg×h/mL for morbidly obese patients; 
P=0.032).35 This finding suggested that it is not necessary to 
adjust the dose of linezolid in people with a weight #150 kg.35 
Another study compared the pharmacokinetics of linezolid in 
five obese adults (BMI .35 kg/m2) before and after Roux-
en-Y gastric bypass surgery (RYGBS).36
According to the results, serum exposure for the anti-
microbial agent was approximately 50% lower than that 
of the nonobese population, which suggested that obese 
patients could require a personalized dose adjustment. These 
differences were maintained when the pharmacokinetic 
parameters were compared prior to the surgical procedure 
with population data (mean [SD] AUC
0–∞ with oral linezolid 
before RYGBS was 41.6 [20.9] mg×h/L compared with 98.9 
[24.7] mg×h/L after RYGBS [P,0.001]).36 However, there is 
still no dosage regimen for oxazolidinones in obese people, 
given that pharmacokinetics in this population is commonly 
unpredictable and determined by other comorbidities such 
as renal failure.37
Regarding renal failure,38 the pharmacokinetics of 
administering a single dose of IV tedizolid was similar 
in patients with severe renal impairment without dialysis 
(estimated glomerular filtration rate ,30 mL/min/1.73 m2)39 
and in the control group.
In addition, it was observed that exposure to tedizolid 
was 25% lower in patients with end-stage renal failure than 
that observed in patients with renal failure who did not 
require hemodialysis and in the control group made up of 
healthy subjects. The authors observed no significant dif-
ferences when they compared exposure to tedizolid prior to 
or subsequent to dialysis (C
max
 geometric mean ratio 1.148 
[90% CI: 1.053–1.252]; AUC
0–∞ geometric mean ratio 0.913 
[90% CI: 0.827–1.007]). The dosage loss of the antimicro-
bial agent was lower than 10% in subjects who received 
tedizolid prior to dialysis. This finding paralleled tedizolid’s 
high degree of plasma protein binding, and its elimination 
was less than the 30% observed with linezolid. Thus, its 
pharmacokinetics is independent of the time of administra-
tion with respect to dialysis (before or after). In this regard, 
it differs from linezolid, which should be administered after 
this technique.40
The authors concluded that no dose adjustment is required 
in patients with any degree of renal failure. In this regard, 
it is similar to linezolid, which does not seem to require an 
adjustment in the different stages of renal failure, even though 
approximately 35% of it is excreted by the kidneys (total 
apparent oral Cl of linezolid ranged from 92.5 to 109.6 mL/
min in subjects with 24 hour urinary creatinine clearance 
of 10–39 mL/min, 40–80 mL/min, or .80 mL/min).25,41 
However, having renal function deterioration has been 
associated with higher plasma concentrations of linezolid 
and the development of adverse events such as thrombo-
cytopenia.42 Therefore, follow-up or even monitoring of 
the plasma concentration of linezolid when possible could 
be advisable in these patients.43 Linezolid has also been 
observed to be related to an insufficient plasma concentration 
(minimum drug concentration [C
min
] ,2 mg/L) in patients 
with an estimated glomerular filtration rate higher than 
80 mL/min/1.73 m2.44
This lower exposure to tedizolid in patients with end-
stage chronic renal disease was examined again in a post 
hoc analysis of the data presented.45 To do this, AUC was 
determined for patients with different stages of renal failure 
and correlated with age, sex, and BMI. In addition, IBW was 
calculated for each participating subject. The mean (standard 
deviation) AUC
0–∞ value was 23.27 (7.50) mg×h/mL in the 
end-stage renal disease patients, 29.99 (8.97) mg×h/mL in the 
severe renal impairment patients, and 32.43 (9.53) mg×h/mL 
in the control patients. Exposure to tedizolid was inversely 
proportional to IBW, which explained the lower AUC values 
in patients with end-stage renal disease who showed higher 
IBWs. The authors attributed the lower concentrations of 
tedizolid in these patients with end-stage chronic renal 
disease to the fact that they had a higher IBW. This covari-
ate yielded greater variability in the pharmacokinetics of 
tedizolid, more than a different behavior on the part of the 
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antibiotic in this population, and therefore they confirmed that 
it is not necessary to adjust the doses in renal disease.45
The same authors studied the pharmacokinetics of 
tedizolid after administering a single dose of oral tedizolid 
phosphate 200 mg in patients with moderate or severe 
hepatic failure according to the Child–Pugh classification.38 
They observed minimal differences in the pharmacokinetic 
parameters calculated both between patients with moderate 
hepatic failure and severe hepatic failure and between these 
patients and their controls. The parameter with the most 
variation was the AUC
0–∞ value, which was 34% higher in 
patients with severe hepatic failure (geometric mean ratio 
1.341 [90% CI: 0.927–1.939]) and 22% higher in patients 
with moderate hepatic failure compared to their controls 
(geometric mean ratio 1.216 (90% CI: 0.862–1.716). These 
slight increases in exposure to tedizolid were not associated 
with clinical significance, given its good tolerance, and 
so the authors concluded that it is not necessary to adjust 
the dose of tedizolid in this group of patients. Similarly, 
exposure to linezolid increased by 1.3 times in subjects 
with mild-to-moderate hepatic failure compared to healthy 
subjects. However, this increase was not associated with the 
need for dose titration in this population.46
Pharmacodynamics
The pharmacodynamic behavior of neither tedizolid phos-
phate nor tedizolid has been fully established. One of the 
main studies that sought to evaluate this behavior involved 
tedizolid phosphate/tedizolid dose fractionation studies in a 
neutropenic mouse model with a thigh infection caused by 
methicillin-sensitive S. aureus (MSSA) and MRSA strains.47 
It also compared their activity in vivo versus linezolid. The 
total dose of tedizolid phosphate was provided as equivalent 
doses of tedizolid. The AUC
0–24
/minimum inhibitory con-
centration (MIC), T.MIC, and C
max
/MIC free drug ratios 
were calculated for daily doses of tedizolid phosphate of 
10, 20, 36, and 72 mg/kg/24 h, fractionated into one, two, or 
four daily doses. According to the results, the AUC
0–24
/MIC 
pharmacodynamic ratio achieved the best correlation with 
the efficacy of tedizolid (r2: 0.984), versus the T.MIC ratio 
(r2: 0.624) and the C
max
/MIC ratio (r2: 0.757). Thus, a value 
for the AUC
0–24
/MIC ratio of 49.3 for tedizolid and 105.9 for 
tedizolid phosphate resulted in stasis and in a 1-log CFU/g 
reduction of the bacterial concentration in the thigh at 24 
hours against the ATCC 33591 MRSA strain. At the same 
time, a value for the AUC
0–24
/MIC ratio of 43.1 for tedizolid 
and 56.9 for tedizolid phosphate resulted in stasis and in a 
1-log CFU/g reduction of the bacterial concentration in the 
thigh at 48 hours against the ATCC 33591 MRSA strain. 
In addition, it was estimated that a value for the AUC
0–24
/
MIC ratio of 307.6 for TR-700/TR-701 would result in a 
4.53-log CFU/g reduction and a 5.92-log CFU/g reduc-
tion in the bacterial concentration in the thigh at 24 and 48 
hours, respectively. By contrast, a value for the AUC
0–24
/
MIC ratio of 35.7 obtained after administering 120 mg/kg 
of linezolid did not result in stasis. In addition, no greater 
microbiological effect of linezolid was observed at 48 hours 
versus at 24 hours.
Furthermore, a dose fractionation study was conducted 
for TR-701/TR-700 and for linezolid against an MSSA 
strain and against a community-acquired MRSA strain. 
The linezolid doses evaluated resulted in a lower reduction 
of the bacterial load versus the same doses of TR-701/700 
for both S. aureus strains. Regarding the MRSA strain, 
the 150-mg/kg linezolid dose yielded a value for the 
AUC
0–24
/MIC ratio of 44.6, while stasis was achieved with a 
TR-701/TR-700 dose of 33.8 mg/kg, corresponding to a value 
for the AUC
0–24
/MIC ratio of 44.0. The difference between 
the two dosage regimens roughly corresponded to a 1.1-log 
CFU/g higher reduction in the bacterial load for TR-701/700. 
Regarding the MSSA strain, the 40.6-mg/kg TR-701/700 
dose, corresponding to a value for the AUC
0–24
/MIC ratio of 
52.8, resulted in stasis, while the 150-mg/kg linezolid dose 
(AUC
0–24
/MIC of 44.6) did not achieve this state.
Subsequently, another study was conducted in a nonneu-
tropenic mouse model with an infection caused by the ATCC 
33591 MRSA strain (used in the aforementioned study) with 
the aim of evaluating the impact of granulocytes on the anti-
microbial activity of TR-700.48 According to the results, the 
presence of granulocytes considerably increased the activity 
of TR-700. Thus, administration of TR-701 at an equivalent 
dose of 1,600 mg daily in humans did not result in stasis at 
72 hours when it was administered to the neutropenic model. 
However, the equivalent dose in humans of 3,200 mg daily 
resulted in a reduction of 2.75 log CFU/g in the bacterial load 
(killing rate) at 72 hours, of 1.73 log CFU/g at 48 hours, and 
of 1.0 log CFU/g at 24 hours.
Moreover, administering TR-701 at an equivalent dose 
of 1,200 mg daily in humans resulted in the maximum effect 
at 24 hours in the nonneutropenic model, while this was 
observed with the 800 mg daily dose at 48 hours. Finally, 
the 200 mg daily dose in the nonneutropenic mouse resulted 
in an effect near the maximum at 72 hours. Practically, no 
differences were observed with the 3,200 mg daily dose.
From these studies, it appears that the value for the 
AUC
0–24
/MIC ratio should be lower in immunocompetent 





animal models.49 Thus, a value for the AUC
0–24
/MIC ratio 
of 3 was extrapolated in immunocompetent animals based 
on a value of 50 in a neutropenic model.
Given this, a Monte Carlo simulation was performed with 
the aim of estimating the probability of obtaining a value for 
the AUC
0–24
/MIC ratio of 3 based on pharmacokinetic param-
eters in humans.50 The estimated probability approached zero 
when the microorganism’s MIC was 2 μg/mL or higher. 
Moreover, the probability was above 98% when the micro-
organism’s MIC was 0.5 μg/mL or lower.
Review of microbiology
In general, tedizolid shows high activity against Gram-positive 
microorganisms, including those with limited sensitivity 
to linezolid and other commonly used antibiotics in the 
treatment of infections caused by these bacteria. Tedizolid-
susceptible Staphylococcus spp. and group A, B, C, and G 
Streptococcus strains were considered to be those against 
which the antibiotic’s MIC
90
 was 0.5 mg/L or lower. Resistant 
strains were considered to be those whose MIC
90
 was above 
this value.51 Tedizolid-susceptible Streptococcus anginosus 
group strains were considered to be those against which the 
antibiotic’s MIC
90
 was 0.25 mg/L or lower. Resistant strains 
were considered to be those whose MIC
90
 was above this 
value.51 No MIC
90
 breakpoints were established for Gram-
positive anaerobic microorganisms.51 As with linezolid, 
tedizolid activity against Gram-negative microorganisms is 
very limited.52,53
Gram-positive microorganisms
Tedizolid shows high activity in vitro against strains of 
S. aureus (including MRSA and MSSA strains), S. pyogenes, 
Streptococcus agalactiae, the Streptococcus anginosus 
group (including S. anginosus, Streptococcus intermedius, 
and Streptococcus constellatus), and E. faecalis (FDA fact 
sheet). Tedizolid’s MIC is 0.5 mg/L or lower against these 
microorganisms and achieves a value of 0.25 mg/L or lower 
in the case of S. anginosus group strains (FDA fact sheet). 
These values demonstrate activity that is generally 
two to four times higher than that of linezolid. 54–59 In one 
study, tedizolid’s MIC range was 0.125–0.5 mg/L against 
MRSA strains from SSSIs, while linezolid’s MIC range 
was 0.25–4 mg/L.54 The most effective drugs against MRSA 
were tedizolid (MIC
90
 of 0.5 mg/L), linezolid (MIC
90
 of 
2 mg/L), and vancomycin (MIC
90
 of 2 mg/L). Similar results 





 for both MRSA and MSSA were 
2 mg/L,55 and 0.5 mg/L,55,56 respectively. Lower values have 
been reported, with tedizolid’s MIC
90
 for both MRSA and 
MSSA of 0.25 mg/L, compared with a MIC
90




 for both methicillin-resistant (MRSE) and 
methicillin-susceptible S. epidermidis (MSSE) was 0.5 mg/L 
against 74 clinical isolates of this microorganism (MIC 
range 0.06–0.5 mg/L).55 The MIC
90
 values were 0.25 and 
0.5 mg/L for S. epidermidis and other coagulase-negative 
staphylococci included in other study, respectively.56 These 
values were lower than those for vancomycin (MIC
90
 
was 4 and 2 mg/L for MRSE and MSSE, respectively)55 
or linezolid (MIC
90
 was 1 mg/L for S. epidermidis and 
2 mg/L for other coagulase-negative staphylococci).56
At the same time, tedizolid’s MIC range was 0.25–0.5 mg/L 
for Enterococcus spp. strains, while linezolid’s MIC range 
was 0.5–2 mg/L.54 Tedizolid MIC
90
 value was 0.5 mg/L 
against 873 enterococci included in other study while lin-
ezolid’s MIC
90
 was 2 mg/L.56
Finally, tedizolid’s MIC range was 0.25–0.5 mg/L for 
S. agalactiae strains and 0.125–0.5 mg/L for S. pyogenes 
strains, while linezolid’s MIC range was 2–4 mg/L for 
S. agalactiae strains and 1–2 mg/L for S. pyogenes strains.54 
Tedizolid MIC
90
 values for S. agalactiae, S. pyogenes, and 
other β-hemolytic streptococci were each 0.25 mg/L, whereas 
linezolid’s MIC
90
 was 1 mg/L.56,58
Although tedizolid has high activity in vitro against 
Gram-positive microorganisms, this activity is very limited 
against biofilm-forming bacteria.55 Similar to linezolid, tedi-
zolid could show synergistic activity with rifampin.
Mechanisms of resistance to tedizolid
Various mechanisms of resistance against oxazolidinones 
have been reported. Notable among them are mutations in the 
genes that encode 23S rRNA60,61 or the ribosomal proteins L3 
(rplC) and L4 (rplD)62–64 and horizontal transmission of the 
chloramphenicol–florfenicol resistance (cfr) gene.65,66
In general, the microorganisms that show resistance 
against oxazolidinones because of mutations in the chro-
mosomal genes that encode 23S rRNA or the L3 and L4 
ribosomal proteins show cross-resistance to tedizolid (FDA 
fact sheet). However, in the absence of these chromosomal 
mutations, the presence of the cfr gene did not result in resis-
tance to tedizolid in the limited number of S. aureus strains 
evaluated (FDA fact sheet). It has been observed that the 
frequency of spontaneous mutation that grants resistance to 
tedizolid is approximately 10-10 (FDA fact sheet).
Similar values were observed in another study that sought 
to evaluate the potential of one strain of MSSA and another 
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six alleles. In both S. aureus and E. faecium and E. faecalis 
strains, a correlation has been reported between successive 
accumulation of the G2576T mutation in the different copies 
of the gene that encodes the 23S rRNA and a gradual increase 
in the level of resistance to linezolid.68,69 In this study, tedi-
zolid’s MIC against the aforementioned strains ranged from 
8 to 64 mg/L. Moreover, the S. epidermidis strain had the 
L101V, H146Q, V154L, and A157R mutations in the gene 
that codes for the L3 protein, and the 71G72 insertion and 
the N158S mutation in the gene that codes for the L4 protein. 
Among them, the L101V mutation and the N158S mutation 
seem to be associated with a lower impact on the develop-
ment of resistance to oxazolidinones.
Finally, the NRS127 S. aureus strain had a deletion of 
the serine in position 145 of the gene that codes for L3, the 
IDRL-0025 S. aureus strain had the G152D mutation, and 
the NRS271 S. aureus strain had the Q3K mutation in the 
gene that codes for this protein.
In addition to the aforementioned mechanisms of resis-
tance, a new mechanism of resistance to oxazolidinones was 
recently identified in E. faecalis and E. faecium strains.70 
This mechanism consists of the presence of the optrA gene, 
located in plasmids, which codes for an ABC transporter that 
grants resistance to phenicols as well as to oxazolidinones. 
With the aim of finding out the prevalence of this gene, 595 
Enterococcus spp. strains from humans and 290 strains from 
animals were included. The optrA gene was identified in 12 
(2%) of the strains from humans and in 46 (15.9%) of the 
strains from animals. These data highlight the significance 
of monitoring the use of florfenicol in the production of 
animal feed. In addition, they emphasize the importance of 
monitoring the presence of this gene in Enterococcus spp. 
strains with a high MIC for linezolid and tedizolid, in addition 
to cfr gene carrier status and mutations at the 23S rRNA.
Gram-positive microorganisms with 
limited susceptibility versus commonly 
used antibiotics
Tedizolid has shown high activity in vitro against strains 
of Gram-positive microorganisms with limited sensitivity 
to commonly used antibiotics in infections caused by these 
microorganisms.56,57,71 Tedizolid activity was four to eight 
times higher than that observed with linezolid in one study 
that included 302 MRSA strains and 220 vancomycin-
resistant (VR) Enterococcus spp. strains.71 Tedizolid MIC
90
 
values for heterogenous vancomycin-intermediate MRSA 
(n=120), vancomycin-intermediate MRSA (n=100), and 
daptomycin-non-susceptible MRSA (n=75) were 0.5 mg/L 
strain of MRSA to develop resistance against tedizolid and 
linezolid by analyzing the spontaneous mutation rates and 
serial passage of these strains in media with an escalating 
concentration gradient of these oxazolidinones.62 The 
median spontaneous mutation rate that resulted in a reduc-
tion in sensitivity to tedizolid was 1.1×10-10 for the MSSA 
strain and 1.9×10-10 for the MRSA strain. These values 
were approximately 16 times lower than those reported for 
linezolid because a median spontaneous mutation rate of 
2.0×10-9 was found for the MSSA strain and 3.0×10-9 was 
found for the MRSA strain. The mutant strains selected 
through exposure to tedizolid had the T2500A mutation and 
the coupled T2571C/G2576T mutation at the 23S rRNA, 
while the mutant strains selected through exposure to lin-
ezolid had the G2447T, G2576T, and T2500A mutations. In 
addition, mutations were identified in the rplC gene, which 
encodes the L3 ribosomal protein, and the rplD gene, 
which encodes the L4 ribosomal protein. The Gly152Asp, 
Gly155Arg, Gly155Arg/Met169Leu, and ΔPhe127-His146 
mutations were identified in L3, and the Lys68Gln mutation 
was identified in L4.
In addition, serial passage of the MSSA and MRSA 
strains was performed in a concentration gradient of tedizolid 
and linezolid. Following 30 passages in these media, tedi-
zolid’s MIC against the MSSA strain remained at 0.5 μg/mL, 
while linezolid’s MIC increased from 2 to 128 μg/mL. 
A reduction in sensitivity to linezolid was observed follow-
ing five passages in a medium with linezolid, associated with 
the Gly155Arg mutation in L3. Subsequent passages in this 
medium resulted in mutant MSSA strains with the G2447T 
mutation in the rRNA or the G2447T mutation coupled 
with the Gly152Asp mutation in L3. Similarly, against the 
MRSA strain, tedizolid’s MIC increased by eight times 
(from 0.25 to 2 μg/mL), while linezolid’s MIC increased 
32 times (from 1 to 32 μg/mL). The reduction in sensitivity 
to these antibiotics in the MRSA strain was associated with 
the Lys68Gln mutation in L4 and the G2576T mutation in 
the rRNA in the case of linezolid and the double T25761C/
G2576T mutation at the 23S rRNA in the case of tedizolid.
Recently, another study sought to characterize the mecha-
nism of resistance against oxazolidinones of 27 strains of 
Gram-positive linezolid-resistant microorganisms, as well as to 
evaluate the microbiological activity of tedizolid against these 
bacteria.67 Altogether, five S. aureus strains, 21 E. faecium 
strains, and one S. epidermidis strain were included.
The IDRL-10060, NRS271, and NRS119 S. aureus strains 
and all E. faecium strains had the G2576T mutation at the 
23S rRNA. This mutation was identified in at least five of the 





versus 4, 4, and 2 mg/L for linezolid, respectively.71 When 
only the linezolid-resistant MRSA strains were evaluated 
(n=7), tedizolid MIC ranged from ,0.063 to 1 mg/L. Three 
of these strains had a MIC of 1 mg/L versus tedizolid and 
all lacked the cfr gene, so the reduction in sensitivity to 
tedizolid could be attributed to an alternative mechanism, 
such as mutations in the 23S ribosomal RNA or in L3 and L4 
ribosomal proteins.
The 98.3% of all staphylococci strains were inhibited by 
tedizolid MIC value of 0.5 mg/L. Rates of susceptibility to 
other common antimicrobials were: clindamycin (32.3%), 
levofloxacin (19.9%), oxacillin (0%), tigecycline (98.9%), 
and trimethoprim/sulfamethoxazole (79.1%). 
Tedizolid MIC
90
 values for VR E. faecium (n=120) and 
E. faecalis (n=100) were 1 mg/L and 0.25 mg/L, respectively. 
These values were two dilutions lower for E. faecium and 
three dilutions lower for E. faecalis compared with linezolid. 
When linezolid-resistant enterococcal strains were evaluated 
(10 E. faecium strains), tedizolid MIC values ranged from 1 
to 4 mg/L (linezolid MIC values ranged from 8 to 32 mg/L). 
None of these 10 strains was cfr positive. Similarly, among 
daptomycin-non-susceptible VR enterococcal strains (25 E. 
faecium strains), tedizolid MIC values ranged from 0.25 to 
4 mg/L (56% with MIC values ,1 mg/L) (linezolid MIC 
range was 1 to 32 mg/L).
Tedizolid’s MIC was 0.5 mg/L against three of four 
S. aureus strains that were linezolid resistant owing to being 
cfr gene carriers, and 1 mg/L for the fourth strain carry-
ing this gene.56 These values were 16–32 times lower than 
those observed with linezolid. However, tedizolid showed 
no activity against three strains that were linezolid-resistant 
owing to a mutation at the 23S rRNA (one strain carrying 
a mutant G2405A allele and two mutant G2576T alleles, 
one strain carrying three mutated G2576T alleles, and one 
strain carrying four mutated G2576T alleles). Tedizolid’s 
MIC against these strains was 2 mg/L, and linezolid’s MIC 
against these strains was 16 mg/L.
Tedizolid MIC values were 4 mg/L for four of five 
linezolid-resistant S. epidermidis strains and 8 mg/L for the 
remaining strain (linezolid MIC values ranged from 32 to 
128 mg/L).56
In another study, tedizolid maintained its activity against 
linezolid-resistant coagulase-negative Staphylococcus strains 
when the mechanism involved was cfr gene carrier status.57 
However, higher MICs for tedizolid were observed when the 
mechanism of resistance identified was the G2576T muta-
tion. Finally, linezolid’s MIC was 2–5 doubling dilutions 
higher than that of tedizolid against Staphylococcus spp. and 
linezolid-resistant Enterococcus spp. strains included in 
another study.67 Tedizolid’s MIC ranged from 1 to 8 mg/L 
against five linezolid-resistant S. aureus strains, while 
linezolid’s MIC ranged from 8 to 64 mg/L. At the same 
time, tedizolid’s MIC was 1 to 4 mg/L against 21 linezolid-
resistant E. faecium strains, while linezolid’s MIC was 8 to 
64 mg/L. Finally, tedizolid’s MIC was 2 mg/L against the 
linezolid-resistant S. epidermidis strain included in the study, 
while linezolid’s MIC was 32 mg/L.
In general, although activity of tedizolid is higher 
against linezolid-resistant Gram-positive microorganisms, 
limited sensitivity to tedizolid must be considered when 
the mechanisms of resistance involved are mutations in the 
genes that code for the 23S rRNA, the rplC gene, and/or the 
rplD gene.56,57,67,71
Anaerobic microorganisms
Tedizolid shows excellent activity against anaerobic Gram-
positive microorganisms.54 Tedizolid’s MIC range against 
these microorganisms was four to eight times lower than 
that observed with linezolid.
Clinical	efficacy
A limited number of studies have evaluated the efficacy of 
tedizolid in ABSSSIs. To date, one Phase II study and two 
Phase III studies have been completed. All were conducted 
according to the FDA guidance document for the develop-
ment of new compounds in ABSSSIs.
Phase ii study
A Phase II, randomized, double-blind, clinical trial sought 
to evaluate the efficacy of tedizolid phosphate administered 
at doses of 200, 300, and 400 mg once daily for 5–7 days 
in patients with SSSIs.72 Subsequently, the microbiological 
activity of tedizolid and linezolid and the microbiological 
efficacy of tedizolid against isolated Gram-positive microor-
ganisms in cultures from patients enrolled in the aforemen-
tioned study were evaluated.58
Between September 2008 and January 2009, a total of 
192 patients were randomized; 188 of them received at 
least one dose of tedizolid phosphate and had a diagnosis 
of complicated SSSI (modified intention-to-treat [IIT] and 
clinical modified IIT, respectively).72 In addition, another 
three study populations were identified: the microbiologi-
cal modified intention-to-treat (mMITT) population, which 
comprised patients enrolled in the clinical modified IIT 
population who also had isolation of a Gram-positive micro-
organism at baseline, and the clinically evaluable population, 
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which comprised those patients who received the minimum 
requirement of study drug and were clinically evaluated at 
the test-of-cure (TOC) visit. Finally, the microbiologically 
evaluable (ME) population was made up of those patients 
included in both the clinically evaluable population and the 
mMITT population. Thus, 164 patients were included in 
the clinically evaluable population, 154 were included in 
the mMITT population, and 133 were included in the ME 
population.
The clinical cure rate at the (TOC) visit (7–14 days 
after the end of treatment [EOT]) in clinically evaluable 
patients was 98.2% for the group that received tedizolid 
phosphate 200 mg and 94.4% for the group that received 300 
or 400 mg of the antibiotic. No differences were observed 
based on the type and size of the lesion or the seriousness 
of the infection.
S. aureus strains were isolated in 139 (90.3%) of the 
154 patients included in the mMITT population; 112 (80.6%) 
of these were MRSA strains.58
Similarly, S. aureus strains were isolated in 119 (89.5%) of 
the 133 patients included in the ME population; 94 (79.0%) 
of these were MRSA strains.58 In this group, a similar rate 
of microbiological eradication was observed for all tedi-
zolid dose groups at the TOC visit. A value of 97.7% was 
achieved when all isolated microorganisms were taken into 
account, a value of 97.9% was achieved when only MRSA 
strains were taken into account, and a value of 95.7% was 
achieved for MSSA strains.58 When only S. aureus strains 
were considered, the clinical cure rate in the ME population 
was 96.6% at the TOC visit, and reached a value of 96.9% 
when only MRSA strains were considered and a value of 
95.7% for MSSA strains.58
Phase iii studies
eSTABLiSH-1
A randomized, double-blind, double-dummy, multicenter, 
multinational study designed with the aim of establishing the 
noninferiority of once-daily oral administration of tedizolid 
phosphate 200 mg for 6 days versus oral administration of 
linezolid 600 mg every 12 hours for 10 days in the treat-
ment of ABSSSIs.73 The main objective of the study was to 
evaluate early clinical response to treatment at 48–72 hours 
after the first dose of study antibiotic in the ITT analysis set. 
Secondary objectives included evaluating clinical response 
in the ITT analysis set and in the clinically evaluable analy-
sis set both at the EOT (day 11) and at 7–14 days from the 
EOT. The clinically evaluable analysis set included all 
patients included in the ITT analysis set who complied with 
the protocol without major violations and who completed 
specific evaluations for a particular objective. A total of 
667 patients aged 18 years or older were randomized to 
receive tedizolid phosphate or linezolid between August 12, 
2010 and September 30, 2011 and formed the ITT analysis 
set. At the same time, the clinically evaluable analysis set 
both at the EOT and at 7–14 days from the EOT was formed 
by 559 patients. In the ITT analysis set, the clinical response 
rates at 48–72 hours were 79.5% (95% CI: 74.8%–83.7%) 
of 332 patients in the tedizolid phosphate group and 79.4% 
(95% CI: 74.7%–83.6%) of 335 patients in the linezolid 
group (a treatment difference of 0.1% [95% CI: –6.1%–6.2%]). 
Sustained clinical treatment response rates at the EOT were 
similar in the tezidolid phosphate and linezolid groups in 
the ITT analysis set (69.3% and 71.9%, respectively) and 
in the clinically evaluable analysis set (80.2% and 81.1%, 
respectively). Results of investigator-assessed clinical treat-
ment response 1–2 weeks after the EOT were also similar 
in the tedizolid phosphate and linezolid groups in the ITT 
analysis set (85.5% and 86.0%, respectively) and in the 
clinically evaluable analysis set (94.6% and 95.4%, respec-
tively). In addition, no differences in clinical response rate 
were observed at 7–14 days after the EOT assessed by the 
investigator based on the isolated S. aureus strain (MRSA 
strains: 75/88 [85.2%] for tedizolid phosphate versus 77/90 
[85.6%] for linezolid; MSSA strains: 73/83 [88.0%] for 
tedizolid phosphate versus 82/87 [94.3%] for linezolid; 
strains positive for the Panton–Valentine leukocidin gene: 
83/97 [85.6%] for tedizolid phosphate versus 86/102 [84.3%] 
for linezolid).
eSTABLiSH-2
A randomized, double-blind, multinational, noninferior-
ity, parallel-group design study with the aim of evaluating 
the efficacy of once-daily intravenous administration of 
tedizolid phosphate 200 mg for 6 days versus intravenous 
administration of linezolid 600 mg every 12 hours for 
10 days in the treatment of ABSSSIs, with the possibility 
of sequential oral therapy.74 The main objective of the study 
was to evaluate early clinical response at 48–72 hours after 
the first dose of study antibiotic in the IIT analysis set. 
Secondary objectives included evaluating clinical response 
on day 7 (assessed by the investigator), at the EOT (deter-
mined by the schedule and assessed by the investigator) 
and at 7–14 days after the EOT (assessed by the investiga-
tor). A total of 666 patients were randomized to receive 
tedizolid (n=332) or linezolid (n=334) between September 
28, 2011 and January 10, 2013. Sequential therapy from 





intravenous tedizolid to oral tedizolid was not inferior to 
linezolid (283 [85%] participants in the tedizolid group and 
276 [83%] of those in the linezolid group achieved early 
clinical response). Results were consistent with investigator 
assessment (Table 2).
These results were maintained when microbiologi-
cal response was evaluated at 7–14 days after the EOT in 
patients enrolled in the microbiological IIT population, which 
comprised those patients who received at least one dose 
of antimicrobial agent who also had isolation of a Gram-
positive microorganism at baseline. In total, 168 (88%) of 
192 patients enrolled in the tedizolid phosphate group versus 
177 (89%) of 199 patients enrolled in the linezolid group had 
a favorable microbiological response at 7–14 days following 
the EOT (-1.4 [95% CI: -8.0 to 5.1]). The noninferiority 
of tedizolid phosphate was maintained when the isolated 
Gram-positive microorganism corresponded to MRSA 
strains (43/53 [81.0%] versus 43/56 [77.0%]; 95% CI: 4.3 
[-11.4 to 19.8]).
With the aim of optimizing evaluation of the effi-
cacy of tedizolid and linezolid, one study conducted an 
aggregate data analysis for both Phase III trials.59 A total of 
1,333 patients were randomized to receive treatment with 
tedizolid 200 mg once daily for 6 days (n=664) or linezolid 
600 mg every 12 hours for 10 days (n=669). A total of 
1,225 patients (91.9%) completed the study; 612 of them 
belonged to the tedizolid arm and 613 of them belonged to 
the linezolid arm. In the aggregate data analysis, tedizolid 
was not inferior to linezolid in the clinical response at 
48–72 hours evaluated in the IIT population (81.6% versus 
79.4%; difference: 2.2% [95% CI: -2.0 to 6.5]). Regarding 
the secondary objectives, tedizolid was not inferior to lin-
ezolid in the clinical response determined by the schedule 
at the EOT (87.0% versus 87.9%; difference: -0.8% [95% 
CI: -4.4 to 2.7]) or in the clinical response assessed by the 
investigator at 7–14 days following the EOT (86.7% versus 
86.8%; difference: -0.1 [95% CI: -3.8 to 3.6]). The clinical 
response at 48–72 hours and at 7–14 days following the EOT 
was similarly independent of the Gram-positive microor-
ganism isolated. Regarding patients with MRSA isolation, 
114 (80.9%) of 141 patients who received treatment with 
tedizolid had a clinical response at 48–72 hours, versus 
111 (76.0%) of 146 patients who received treatment with 
linezolid. At the same time, in this group, clinical response 
was observed at 7–14 days from the EOT in 151 (84.8%) 
of 178 patients who received tedizolid versus 119 (81.5%) 
of 146 patients who received linezolid.
The noninferiority of tedizolid versus linezolid was 
also demonstrated in a post hoc analysis of Latino patients 
enrolled in the ESTABLISH-1 and ESTABLISH-2 trials.75
Currently, further clinical trials are being conducted 
with the aim of evaluating the efficacy of tedizolid in 
ABSSSIs.76
Tolerability
In a study by Leach et al,17 oxazolidinones were observed 
to be cross-linked to RNA in the peptidyltransferase center 
of mitochondrial ribosomes instead of cytoplasmic ribo-
somes. This led to the inhibition of mitochondrial protein 
synthesis, which has been associated with mitochondrial 
toxicity, and to a wide variety of adverse events, such as 
myelosuppression, lactic acidosis, optic neuropathy, and 
peripheral neuropathy.77–79
McKee et al80 evaluated the capacity of different 
oxazolidinones to inhibit mitochondrial protein synthesis 
in the heart and liver in a mouse model, and in the heart 
and bone marrow in rabbits. According to the results, mito-
chondrial inhibition was similar in all tissues.80 In addition, 
their data indicated that oxazolidinones with higher antimi-
crobial activity (lower MICs) also demonstrated a greater 
Table 2 investigator-assessed clinical success rates






48–72 hours* 304 (92%) 302 (90%) 1.2% (-3.3 to 5.6) 
Day 7* 309 (93%) 308 (92%) 0.9% (-3.2 to 4.9) 
end of treatment (day 11)† 304 (92%) 301 (90%) 1.4% (-3.0 to 5.9) 
Post-therapy assessment (7–14 days after end of treatment)† 292 (88%) 293 (88%) 0.3% (-4.8 to 5.3) 
Late follow-up (18–25 days after end of treatment)‡ 262/268 (98%) 266/269 (99%) -1.1% (-3.8 to 1.3) 
Notes: Reprinted from The Lancet Infectious Diseases; 14(8); Moran GJ, Fang e, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 
10 days for acute bacterial skin and skin-structure infections (eSTABLiSH-2): a randomised, double-blind, phase 3, non-inferiority trial; pages 696–705. Copyright 2014, 
with permission from elsevier.74	Data	are	n	(%),	unless	otherwise	indicated.	*Clinical	success	defined	as	improvement	in	overall	clinical	status	of	ABSSSI	compatible	with	
continuation of study drug. †Clinical	success	defined	as	resolution	or	near	resolution	of	disease-specific	signs	and	symptoms,	absence	or	near	resolution	of	baseline	systemic	
signs	of	infection,	and	no	further	antibiotic	treatment	required	for	treatment	of	primary	ABSSSI	lesion.	‡Clinical	success	defined	as	no	new	signs	or	symptoms	of	primary	
ABSSSi after posttherapy assessment. Only assessed in patients who were clinically evaluable and deemed clinical successes at posttherapy assessment.
Abbreviations:	ABSSSI,	acute	bacterial	skin	and	skin-structure	infection;	CI,	confidence	interval.
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capacity for protein synthesis inhibition. However, some 
oxazolidinones that demonstrated a high capacity for inhib-
iting mitochondrial protein synthesis did not have powerful 
antibacterial activity.
Flanagan et al81 found a relationship between trough-
free concentrations (C
min
) of linezolid and a greater risk of 
adverse effects. This is because a C
min
 higher than the IC
50
 
without recovery time has been associated with mitochon-
drial toxicity.81 Similarly, an association between an higher 
C
min
 of linezolid and lower mitochondrial function has been 
observed in other studies,82 and this fact has been associated 
with a greater proportion of adverse events related to mito-
chondrial toxicity.
In addition to C
min
, treatment duration83 is among the 
variables related to the potential onset of adverse events 
associated with mitochondrial toxicity. Therefore, the use-
fulness of monitoring plasma levels of linezolid, mainly in 
patients with risk factors for toxicity, such as variation in its 
regular dosage regimen in certain clinical situations (use of 
high doses or continuous infusion), and hepatic and/or renal 
failure, has been established.37,84
Given these data, Flanagan et al85 evaluated the capac-
ity of the new oxazolidinone tedizolid to cause mitochon-
drial toxicity in a mouse model through pharmacokinetic 
studies. Tedizolid in vitro demonstrated more powerful 
dose- and time-dependent mitochondrial protein synthesis 
inhibition than linezolid.86 However, in the results, which 
compared the effect of several supratherapeutic doses of 
tedizolid, with plasma exposure up to eight times greater 
than human therapeutic plasma exposure versus placebo, 
there was no evidence of abnormalities in behavior caused 
by neuropathic damage or of histopathological changes in the 
central or peripheral nervous system caused by oxazolidinone 
following a detailed analysis of brain, eye, optic nerve, spinal 
cord, and peripheral nerve tissue.86
This contrasted with the development of optic and 
peripheral neuropathy observed in rats following 3 months 
of administration of linezolid at doses that provided plasma 
levels comparable to those provided by therapeutic doses in 
humans, which suggested a lower neuropathological profile 
for tedizolid versus linezolid.
Further analyses performed by the same group sug-
gested more rapid dissociation and partial migration of 
mitochondrial impairment over the course of a dosing interval 
for tedizolid versus linezolid. The pharmacokinetic profile 
of tedizolid, which allows for once-daily administration, 
and an effective therapeutic dose of 200 mg, six times lower 
than linezolid (1,200 mg), would explain this behavior.85 
However, caution is required in prolonged treatments, given 
the absence of data for tedizolid administered for periods 
longer than 21 days.
Recently, Milosevic et al87 evaluated tedizolid’s capacity 
to inhibit the expression of proteins encoded by mitochondrial 
genes in cell cultures, with the aim of simulating administra-
tion in human beings to evaluate the impact of oxazolidinone 
on mitochondrial metabolism. The authors of this study 
concluded that tedizolid caused mitochondrial metabolic 
abnormalities in vitro that were related to the dysfunction 
observed in protein expression encoded by the mitochon-
drial genome. However, the clinical impact was limited by 
fast recovery upon washout of the drug, especially when 
tedizolid was used for short periods of time and owing to its 
pharmacokinetic characteristics that allowed its administra-
tion in a single daily dose.
One of the main consequences of mitochondrial toxicity 
is potential myelosuppression. The hematological toxic-
ity of tedizolid was evaluated in detail in a study by Shorr 
et al73 that comprised 1,333 patients previously enrolled in 
two Phase III studies73,74 that compared this antimicrobial 
agent (n=664) versus linezolid (n=669). This study also 
evaluated treatment-emergent adverse events and clinical 
laboratory parameters.
Regarding hematological parameters, changes over time 
in platelet counts, neutrophil counts, and hemoglobin were 
analyzed. According to the results, a platelet count lower 
than 150,000/mm3 was observed on days 7–9 of treatment 
in 3.7% of patients who received tedizolid versus 5.8% of 
those who received linezolid. This difference increased 
to 4.9% of patients who received tedizolid and 10.8% of 
patients who received linezolid at the EOT. The authors 
believed that this difference between tedizolid and linezolid 
was substantial and paralleled the results of Phase I studies, 
in which hematological toxicity was not developed in any 
cell line following administration of tedizolid 200 mg for 
21 days.88 However, these results should be confirmed in 
prolonged treatments with tedizolid.
Regarding treatment-emergent adverse events, similar 
rates were reported in the two groups (42.8% for tedizolid 
versus 43.2% for linezolid). Only 2% of all these adverse 
events were considered to be serious, requiring discontinua-
tion of treatment in 0.5% of patients treated with tedizolid and 
0.9% of patients treated with linezolid. The most commonly 
reported adverse events were gastrointestinal abnormalities 
(16% for tedizolid versus 23% for linezolid), notably nausea 
(8.2% for tedizolid versus 12.2% for linezolid). Also reported 
were headache (6.2% for tedizolid versus 5.9% for linezolid) 





and abscess (5.3% for tedizolid versus 3.9% for linezolid). No 
differences were observed in terms of physical examination 
or electrocardiogram data.89
Drug interactions
One characteristic shared by oxazolidinones is their capac-
ity to inhibit MAO, an enzyme responsible for the metabo-
lism of the neurotransmitters epinephrine, norepinephrine, 
and serotonin (MAO A) and dopamine (MAO B). MAO 
inhibitors may give rise to interactions with foods and other 
drugs, resulting in the so-called serotonin syndrome.90 This 
syndrome results from the accumulation of serotonin, which 
causes an increase in serotonin neurotransmission in both 
the central nervous system central and peripheral serotonin 
receptors. It is very serious, given that it may be fatal in 
some cases.
Linezolid is a competitive and reversible nonselective 
MAO inhibitor, and the onset of serotonin syndrome has been 
reported following its administration together with certain 
serotonergic drugs.91,92 Given this, the FDA indicated that 
“linezolid should generally not be given to patients taking 
serotonergic drugs unless the benefit is deemed to outweigh 
the risk.”93
Although tedizolid has shown a capacity to non-
selectively inhibit MAO in in vitro studies, similar to linezolid, 
studies in a mouse model have not managed to demonstrate 
serotoninergic activity with clinical repercussions.94 However, 
owing to the short duration of the clinical trials, the limited 
number of participants, and the exclusion of other concomitant 
serotonergic drugs, some authors have not ruled out the poten-
tial onset of serotonin toxicity in the future.95
MAO inhibitors may increase blood pressure when 
they are administered together with vasoconstrictors such 
as tyramine or pseudoephedrine, and they may trigger 
hypertensive crises. The potential interaction between tedi-
zolid and oral tyramine and pseudoephedrine was evaluated 
in two randomized, double-blind, placebo-controlled cross-
over studies.94 In the first day, subjects were randomized 
to administration of tedizolid 200 mg or placebo. On the 
third day, they received tyramine at the dose required to 
cause an increase in systolic blood pressure $30 mmHg. 
According to the results, administration of tedizolid did not 
result in a potentiation of the hypertensive effect of tyramine, 
given that the sensitivity ratio reached was 1.33, ,2, a ratio 
with clinical significance. Only one subject reached a sensi-
tivity ratio .2 (2.1), and palpitations were reported at some 
point in the study in 25 (83.3%) for 30 subjects enrolled. 
This effect may be attributed to tyramine. By contrast, eight 
(80%) of ten subjects who received linezolid had a ratio .2 
(range: 1.50–5.0).96
The authors concluded that it is not necessary to take 
special precautions when tedizolid is administered with 
tyramine-rich foods, given that foods do not tend to contain 
more than 40 mg of the amino acid.
When coadministration of tedizolid with pseudoephedrine 
was studied, no significant changes in blood pressure or 
heart rate were observed between the control group and 
the group that received placebo.94 The profile found was 
somewhat more beneficial than that observed with linezolid, 
which was associated with increases in blood pressure when 
it was administered together with pseudoephedrine.97
Benefits and disadvantages 
compared to other oxazolidinone 
antibiotics
Tedizolid shows higher activity than linezolid against 
Gram-positive microorganisms, including those with limited 
sensitivity against commonly used antibiotics in infections 
caused by these bacteria.
One of the characteristics of tedizolid that makes it more 
attractive is its activity against staphylococci strains that con-
tain the cfr gene, given the high capacity for transmission of 
this mechanism of resistance between strains of this species 
and other Gram-positive microorganisms.98 However, the 
frequency of the appearance of strains with this mechanism 
of resistance is limited, and for this reason, linezolid’s MIC 
against Gram-positive microorganisms has remained stable 
in recent years.99 The bioavailability of tedizolid is high, 
both orally and intravenously, similar to linezolid. However, 
tedizolid has more favorable pharmacokinetics, especially 
because of its prolonged biological half-life, which allows 
it to be administered in a single daily dose. In addition, 
administration of tedizolid seems to be associated with a 
lower risk of hematological adverse effects as well as devel-
oping serotonin syndrome when it is administered with other 
drugs related to this syndrome.
According to the results from the clinical trials, admin-
istration of tedizolid phosphate for 6 days was not inferior 
to administration of linezolid for 10 days. Currently, it is 
being evaluated whether this difference in treatment dura-
tion maintains its efficacy in other infectious diseases such 
as pneumonia, with the aim of positioning tedizolid in the 
available antimicrobial arsenal.100 Should these findings be 
confirmed, the use of tedizolid could be associated with 
reduced economic resources mainly deriving from a shorter 
hospital stay.
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